Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
PARACETAMOL , -, -, CARBOPLATIN , -, MK-2870, PEMETREXED
Merck Sharp and Dohme
Non-small Cell Lung Cancer (NSCLC)
1 trial -
PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, -
Lacuna Pharma Pty Ltd
Systemic lupus erythematosus (SLE)
1 trial -
PBO PH20 SC, ARGX-113
argenx
Bullous Pemphigoid
1 trial -
PBSCs
Hospital Authority, Hong Kong
Hematological Malignancies
1 trial -
PCSK9 inhibitors combined with atorvastatin/rosuvastatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Ischemic Stroke
1 trial -
PD-0332991
Pfizer
Breast Neoplasms
1 trial -
PDS Implant with Ranibizumab 100 mg/mL
Hoffmann-La Roche
Neovascular Age-Related Macular Degeneration
1 trial -
PEG-Interferon a-2b + Ribavirin
Universal Integrated
Chronic Hepatitis C Infection in HIV-Infected Persons
1 trial -
PEG-interferon-Alfa-2A
Hospital Authority, Hong Kong
Chronic Hepatitis B
1 trial -
PEGASPARGASE
Pari Pharma GmbH
This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL
1 trial -
PEGCETACOPLAN (APL-2)
Apellis Europe B.V.
Geographic Atrophy Secondary to Age-related Macular Degeneration
1 trial -
PEGFILGRASTIM , PACLITAXEL , DOXORUBICIN , Rinatabart Sesutecan, GEMCITABINE , TOPOTECAN
Genmab A/S
Platinum-resistant Ovarian Cancer
1 trial -
PEGylated Recombinant Factor VIII
Takeda
Hemophilia A
2 trials -
PEGylated Recombinant factor VIII (rFVIII)
Takeda
Hemophilia A
1 trial -
PEMBROLIZUMAB
Ningbo Cancer Hospital
Squamous cell carcinoma of head and neck
1 trial -
PEMBROLIZUMAB
Ningbo Cancer Hospital
Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.
1 trial -
PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE
Lacuna Pharma Pty Ltd
Triple Negative Breast Cancer
1 trial -
PEMBROLIZUMAB , BNT113
BioNTech SE
Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer
1 trial -
PEMBROLIZUMAB , IMFINZI 50 mg/mL concentrate for solution for infusion., JZP598, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Jazz Pharmaceuticals Ireland Limited
BTC - Biliary Tract Cancer
1 trial -
PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent
Eikon Therapeutics
Advanced Melanoma
1 trial -
PEMBROLIZUMAB , Placebo to match ly, ENFORTUMAB VEDOTIN
Eli Lilly Co.
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
1 trial -
PEMBROLIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN, INFLIXIMAB, PACLITAXEL, MYCOPHENOLATE MOFETIL, GEMCITABINE, Datopotamab deruxtecan, PACLITAXEL ALBUMIN-BOUND
AstraZeneca AB
Triple-negative Breast Cancer
1 trial -
PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN
Bristol-Myers Squibb Australia Pty Ltd
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
1 trial -
PEMETREXED , GEMCITABINE , PACLITAXEL , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion.
Partner Therapeutics Limited
Stage IIB-IIIB (N2) resectable non small cell lung cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources